QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-did-biodexa-pharmaceuticals-stock-drop-after-hours-despite-big-gain-during-regular-trading

Biodexa's stock dipped 3.67% to $10.50 in after-hours trading following a strong gain during the regular session.

 biodexa-pharmaceuticals--files-for-mixed-shelf-of-up-to-100m

https://www.sec.gov/Archives/edgar/data/1643918/000121465925014255/b923250f3.htm

 biodexa-pharmaceuticals-implements-1-for-10-reverse-adr-split-new-ratio-now-1-adr-to-100k-ordinary-shares

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative produ...

 biodexa-pharma-advances-development-erapa-oral-tablet-formulation-of-rapamycin-to-treat-fap-non-surgically

Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company, reports making significant progress in ...

 biodexa-pharma-files-cta-with-ema-for-serenta-trial-in-patients-with-familial-adenomatous-polyposis

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial inFamilial Adenomatous Polyposis (FAP)Biodexa Pharmaceutica...

 biodexa-pharma-announces-activation-of-first-clinical-study-site-for-serenta-trial-in-patients-with-familial-adenomatous-polyposis

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)Biod...

Core News & Articles
Market-Moving News for June 18th
06/18/2025 11:29:11

SRRK: 23% | Scholar Rock shares are trading higher after a study showed its new drug combination preserves muscle during tirzep...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION